NCT07034508View on ClinicalTrials.gov

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

December 20, 2027

Study Completion Date

December 20, 2029

Conditions
DLBCL - Diffuse Large B Cell Lymphoma
Interventions
DRUG

Polatuzumab Vedotin

Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Rituximab

Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Cyclophosphamide

Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm

DRUG

Doxorubicin

Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Prednisone

Prednisone PO will be administered as per the schedule specified in the respective arm.

Trial Locations (1)

300020

China Institute of Hematology and Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER